Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Original publication

DOI

10.1111/bjh.14066

Type

Journal article

Journal

Br J Haematol

Publication Date

05/2017

Volume

177

Pages

486 - 491

Keywords

TP53 , B-cell prolymphocytic leukaemia, TP53 deletion, idelalisib, prolymphocytic leukaemia, Antineoplastic Combined Chemotherapy Protocols, Comorbidity, Genetic Variation, Humans, Leukemia, Prolymphocytic, B-Cell, Phenotype, Purines, Quinazolinones, Rituximab, Treatment Outcome, Tumor Suppressor Protein p53